Vericiguat improves cardiac remodelling and function in rats with doxorubicin‐induced cardiomyopathy

Vericiguat improves cardiac remodelling and function in rats with doxorubicin‐induced cardiomyopathy

Abstract Purpose Vericiguat, a soluble guanylate cyclase (sGC) stimulator, has been demonstrated effective in improving prognosis of patients with heart failure with reduced ejection fraction. However, there are limited data concerning the effect of vericiguat in patients with doxorubicin (DOX)‐indu...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wen Chen, Ying Wu, Wei Li, Meiyan Song, Kaizu Xu, Meifang Wu, Liming Lin
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Series:	ESC Heart Failure
Subjects:	apoptosis doxorubicin‐induced cardiomyopathy oxidative stress soluble guanylate cyclase vericiguat
Online Access:	https://doi.org/10.1002/ehf2.15186
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Vericiguat – possibly next weapon to overcome heart failure. Review of latest literature
by: Mikolaj Biskupski, et al.
Published: (2024-12-01)

Analysis of research trends and development prospects of soluble guanylate cyclase stimulators/activators: using bibliometric methods
by: Bing Ju Yan, et al.
Published: (2025-06-01)

Clinical Effectiveness and Safety of Vericiguat in Worsening Heart Failure with Reduced Ejection Fraction: A Single-center, Retrospective Analysis in Indian Patients
by: Pankaj Jariwala, et al.
Published: (2025-01-01)

Zagociguat prevented stressor-induced neuromuscular dysfunction, improved mitochondrial physiology, and increased exercise capacity in diverse mitochondrial respiratory chain disease zebrafish models
by: Leonard Burg, et al.
Published: (2025-07-01)

Nitric oxide — soluble guanylate cyclase — cyclic guanosine monophosphate signaling pathway in the pathogenesis of heart failure and search for novel therapeutic targets
by: Zh. D. Kobalava, et al.
Published: (2021-10-01)

Molecular patterns of the NO-sGC-cGMP pathway in progressive and regressive liver fibrosis models
by: Thomas Sorz-Nechay, et al.
Published: (2025-07-01)

Pharmacological effects of a new soluble guanylate cyclase stimulator in experimental pulmonary arterial hypertension
by: V. V. Bykov, et al.
Published: (2023-04-01)

Calcium-sensor proteins but not bicarbonate ion activate retinal photoreceptor membrane guanylyl cyclase in photoreceptors
by: Igor V. Peshenko, et al.
Published: (2024-12-01)

THE ROLE OF CARBON MONOXIDE IN THE REGULATION OF ELECTRICAL AND CONTRACTILE PROPERTIES OF SMOOTH MUSCLE CELLS OF THE GUINEA PIG URETER
by: I. V. Kovalyov, et al.
Published: (2014-02-01)

Clinical profile, associated events and safety of vericiguat in a real‐world cohort: The VERITA study
by: Mario Galván Ruiz, et al.
Published: (2024-12-01)

Practical aspects of vericiguat therapy in patients with heart failure with reduced ejection fraction. Expert council resolution
by: S. A. Boytsov, et al.
Published: (2023-05-01)

Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction
by: Pushpraj Patel, et al.
Published: (2024-12-01)

Switching Strategy in the Management of Patients with Pulmonary Arterial Hypertension. The REPLACE Study Results
by: E. V. Filippov
Published: (2020-12-01)

Utility of green chemistry for spectrofluorometric and spectrophotometric analysis of vericiguat via reaction with erythrocin B
by: Hesham Salem, et al.
Published: (2025-05-01)

Doxorubicin induced reversible cardiomyopathy: A Case report
by: K Tamakuwala, et al.
Published: (2015-07-01)

Soluble Guanylate Cyclase Stimulator, BAY41‐8543: A Promising Approach for the Treatment of Chronic Heart Failure Caused by Pressure and Volume Overload
by: Adriana Martišková, et al.
Published: (2025-04-01)

Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States
by: Stephen J. Greene, et al.
Published: (2025-08-01)

Different Effects of Riociguat and Vericiguat on Pulmonary Vessels and Airways
by: Katharina Nubbemeyer, et al.
Published: (2025-04-01)

Risk factors of doxorubicin-induced cardiomyopathy in non-muscle- invasive bladder cancer
by: I Made Nugraha Gunamanta Sabudi, et al.
Published: (2024-11-01)

Management of Pulmonary Arterial Hypertension: Current Strategies and Future Prospects
by: Munish Sharma, et al.
Published: (2025-03-01)

Antithrombotic Activity of an Indolinone Derivative – a Soluble Guanylate Cyclase Stimulator
by: V. V. Bykov, et al.
Published: (2022-09-01)

Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study
by: Yinge Zhan, et al.
Published: (2025-02-01)

Role of Bee Propolis and Vitamin E in Attenuating Doxorubicin-induced Hepatic Toxicity in Rats
by: Hodhaifa Abdul Mohsin, et al.
Published: (2025-04-01)

Effect of caffeine on heart rate variability parameters in female rats with doxorubicin-induced cardiomyopathy
by: V. V. Mukvych, et al.
Published: (2025-04-01)

Tetrahedral Framework Nucleic Acids Inhibit Oxidative Stress and Cardiomyocyte Apoptosis in Doxorubicin-Induced Cardiotoxicity
by: Pan H, et al.
Published: (2025-07-01)

Heat shock protein 90 mediates the protective effects of vericiguat on myocardial ischemia/reperfusion injury by inhibiting toll-like receptor 4 and c-Jun N-terminal kinases
by: Sijie Pan, et al.
Published: (2025-09-01)

The potential synergistic effect of combining doxorubicin with vorinostat in urothelial carcinoma therapy
by: Cheng-Huang Shen, et al.
Published: (2025-01-01)

Nano-Curcumin Mitigates Doxorubicin-Induced Reproductive Toxicity via Antioxidant, Anti-Apoptosis, and SIRT1-Modulating Effects in Rat Model
by: Noha A. Alshuwayer, et al.
Published: (2025-07-01)

Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial
by: Alberto Esteban-Fernández, et al.
Published: (2025-01-01)

Doxorubicin-Induced Cardiotoxicity: A Comprehensive Update
by: Vasvi Bhutani, et al.
Published: (2025-05-01)

Exploring the synergistic effects of metformin and doxorubicin loaded chitosan nanoparticles for A549 lung cancer therapy
by: Amirreza Nazemiyeh, et al.
Published: (2025-07-01)

The function of PCSK9 in doxorubicin-induced cardiotoxicity and its underlying mechanism
by: Shuai Shi, et al.
Published: (2025-07-01)

Myricetin protects against doxorubicin-induced acute kidney injury in rats by mitigating oxidative damage and apoptotic response
by: Muhammed Talha Karadogan, et al.
Published: (2025-06-01)

The correlation between the level of doxorubicin-induced cardiac damage and serum soluble Fas in an experimental rat model
by: Dogan Kose, et al.
Published: (2018-01-01)

Guanylate cyclase promotes osseointegration by inhibiting oxidative stress and inflammation in aged rats with iron overload
by: Zhou-Shan Tao, et al.
Published: (2024-09-01)

Cardiac Slc25a49‐Mediated Energy Reprogramming Governs Doxorubicin‐Induced Cardiomyopathy through the G6P–AP‐1–Sln Axis
by: Sitong Wan, et al.
Published: (2025-07-01)

Ring Finger Protein 2 Promotes Oxidative Stress and Mitochondrial Dysfunction in Doxorubicin‐Induced Cardiotoxicity Via the Mercaptopyruvate Sulfurtransferase/Hydrogen Sulfide Pathway
by: Yi Zhong, et al.
Published: (2025-08-01)

TACTICS FEATURES OF CONDUCTING AND CHOOSING SPECIFIC THERAPY FOR ADULT PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE
by: O. A. Arkhipova, et al.
Published: (2018-03-01)

Dynamics of pathological changes of myocardial structures of rats under administration of doxorubicin
by: А. G. Rodinskij, et al.
Published: (2015-04-01)

CDC20 protects the heart from doxorubicin-induced cardiotoxicity by modulating CCDC69 degradation
by: Zhenyu Feng, et al.
Published: (2025-03-01)